IGF1R and hepatocellular carcinoma: A phase‐1 clinical trial confirmed CT‐707 disturbed the IGF1R‐YAP axis under hypoxia HCC microenvironment, which might be applied as an effective therapeutic alternative for HCC with PVTT.65